Session: Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia Defining APOBEC-like signature in diffuse large B-cell lymphoma and demonstration of distinct transcriptomic profile. Presenter: Adam Albitar, MD Date: Jun 1, 2026 – – 9 AM – 12PM CDT Abstract: 7075 Poster Board 573 Session Breast Cancer—Metastatic Dominant chromosomal abnormalities in breast cancer
Lake Forest, CA — December 2, 2025 — Genomic Testing Cooperative (GTC), a leading provider of integrated DNA and RNA next-generation sequencing (NGS) solutions for hematologic tumors and liquid biopsy applications, today announced that its work and data will be presented in 12 abstracts at the ASH 2025 Annual Meeting
GTC presented abstracts at the 2025 Annual Meeting of the Society for Neuro-Oncology (SNO). GTC participated in the 30th Annual Meeting & Education Day of the Society for Neuro-Oncology (SNO), held at the Hawaii Convention Center in Honolulu, November 19–23, 2025. Our two presented posters are now available for download.
GTC presented abstracts at ASCO 2025 GTC’s posters from the 2025 Convention of the American Society of Clinical Oncology are now available for download. Please reach out with any questions. Using cell free DNA (cfDNA) and RNA (cfRNA) in the diagnosis and monitoring of primary and metastatic CNS tumors –
GTC presented abstracts at ASCO 2024 GTC’s posters from 2024 Convention of American Society of Clinical Oncology are now available to be downloaded. Please reach out with any questions. Multiple Alternative Splicing of HER2 transcripts and Exon Skipping with Potential Consequences on Function and Antibody-Based Therapy Download Poster Using Cell-Free
Cell-free RNA in liquid biopsy and biomarkers profiling of hematologic and solid tumors.Presenter: Maher Albitar, MD | Genomic Testing CooperativeAbstract: 3047 | Poster: 39June 5, 2022 at 8 AM CT Downloadable poster Combining cell-free RNA (cfRNA) with cell-free total nucleic acid (cfTNA) as a new paradigm for liquid biopsy.Presenter: Maher
GTC scientists collaborate with the NIH on a study just published in the Journal of Clinical Oncology. The publication is titled: Prediction of outcome in CLL patients treated with ibrutinib: development and validation of a four-factor prognostic model. You can read the article here (subscription required). Abstract: PURPOSE Randomized trials established the
GTC research is being presented at ASCO 2020 in the following three abstracts. 1. FGFR expression, fusion and mutation as detected by NGS sequencing of DNA and RNA. * 2. Measuring PD-L1 mRNA expression using targeted next generation sequencing and correlation with interferon pathway activation genes in lung and colorectal
